RNA editing is emerging as a powerful tool and therapeutic modality, with Wave Life Sciences announcing positive clinical data for AATD, and a new wave of companies entering the clinic; the aspiration of bringing efficacious editors to patients is ever closer to becoming a reality.

With the forging of important partnerships like Roche and Ascidian, and significant funding rounds like AIRNA’s $155m oversubscribed series B, the 6th RNA Editing Summit couldn’t come at a better time, returning to Boston this July to advance the discovery and development of RNA modifying therapies.

Uniting 60+ RNA editing leaders from the likes of Korro Bio, Shape Therapeutics, Deep Genomics, HuidaGene Therapeutics, and more, this intimate, focused forum will showcase novel, innovative editing technologies, translational and functional biology, and never-before-seen clinical data.

Join your peers in Platform Biology, Chemistry, and R and D, for an unrivaled learning and networking opportunity to robustly accelerate more pre-clinical RNA editing candidates towards clinical development, as we see the next wave of editors moving closer to patients in need.

URLs:
Brochure: https://go.evvnt.com/3000511-0?pid=11140
Website: https://go.evvnt.com/3000511-1?pid=11140

Prices:
Conference + 2 Workshops (Drug Developer Pricing): USD 4197.00,
Conference + 1 Workshop (Drug Developer Pricing): USD 3598.00,
Conference Only (Drug Developer Pricing): USD 2999.00,
Conference + 2 Workshops (Academic Pricing): USD 3597.00,
Conference + 1 Workshop (Academic Pricing): USD 3098.00,
Conference Only (Academic Pricing): USD 2599.00,
Conference + 2 Workshops (Service Provider Pricing): USD 5097.00,
Conference + 1 Workshop (Service Provider Pricing): USD 4398.00,
Conference Only: USD 3699.00

Speakers: Jacob Borrajo, Founder and Chief Executive Officer, Amber Bio, Steve Seedhouse, Managing Director, Biotech Equity Research, Cantor Fitzgerald, Keay Nakae, Director of Research, Chardan, Tehmina Masud, Vice President and Head of Systems and Target Biology, Deep Genomics, TJ Cradick, Chief Technology Officer, HuidaGene Therapeutics, Anna Dudkina, Independent RNA Editing Expert, Roger Song, Senior Equity Research Analyst, Jefferies, Vincent DiGiacomo, Director, Therapeutic Innovation, Jorna Therapeutics, Venkat Krishnamurthy, Senior Vice President and Head of Platform, Korro Bio, Ram Aiyar, Chief Executive Officer, Korro Bio, Gerard Platenburg, Chief Scientific Officer, ProQR Therapeutics, Andrew Fraley, Chief Innovation Officer, Radar Therapeutics, Robert Deans, Chief Technology Officer, Rett Syndrome Research Trust, Yang Gao, Assistant Professor, Rice University, Brian Booth, Director Computational Biology RNAfix, Shape Therapeutics, Chad Weldy, Instructor, Cardiovascular Medicine, Stanford University, Peter Nell, Chief Execuitve Officer, Stealth Biotech, Peter Beal, Professor, University of Calfornia Davis, Artem Nemudryi, Assistant Professor, University of Florida, Paul Bolno, Chief Executive Officer, Wave Life Sciences

Time: 8:00 am to 4:15 pm